ライフサイエンスコーパス: farnesyl

1 was carried out in 9 steps from trans,trans-farnesyl acetate using a palladium catalyzed decarboxyla

2 epoxylinalool, (Z)-jasmone, 2-acetylpyrrole, farnesyl acetone, geranyl acetone, cadinol, cubenol and

3 Furthermore, several farnesyl alkene substrates were used to generate structu

4 imination of hydrogen diphosphate from (E,E)-farnesyl and dimethylallyl diphosphate (FDP and DMADP) t

5 ed for the DCS-catalyzed turnover of (2Z,6E)-farnesyl and neryl diphosphates, suggested the intermedi

6 4 of the catalytic domain in addition to the farnesyl and polybasic motifs.

7 in the active state, with membrane-anchored farnesyl and unrestrained HVR, the catalytic domain fluc

8 ent of Ras-PDEdelta inhibitors targeting the farnesyl binding pocket of PDEdelta with nanomolar affin

9 Furthermore, these data suggest that the farnesyl binding site in the exit groove may be signific

10 Mutational analysis of the potential farnesyl-binding sites on AIPL1 identified two critical

11 FBMN migration by disrupting the function of farnesyl biosynthetic enzymes.

12 In the first, the ( S)-epoxide of farnesyl bromide is transformed in just three steps to t

13 ofuran analogues were prepared from triepoxy farnesyl bromides by a zinc-initiated reduction-eliminat

14 After diphosphate expulsion, farnesyl cation reacts with the distal 10,11-double bond

15 erate possible carbocations derived from the farnesyl cation, the first reactive intermediate of the

16 ially the same positions as found in the two farnesyl chains in the substrates.

17 , and phosphorylated once more to generate a farnesyl-CoA amphiphile that self-assembles into spheric

18 cally transferring the farnesyl group of the farnesyl-CoA micelle onto a peptide via phosphopantethei

19 d C89R mutation prevented the binding of the farnesyl-Cys probe to AIPL1.

20 C-terminal membrane anchor that comprises a farnesyl-cysteine-methyl-ester and a polybasic domain.

21 and other cis-prenyl transferases (e.g. cis-farnesyl, decaprenyl, undecaprenyl diphosphate synthases

22 VPS35 bound to N-Ras in a farnesyl-dependent, but neither palmitoyl- nor guanosine

23 ion of the recombinant protein, SAV_76, with farnesyl diphosphate (1, FPP) in the presence of Mg(2+)

24 erea, catalyzes the multistep cyclization of farnesyl diphosphate (2) to the tricyclic sesquiterpene

25 color catalyzes the multistep cyclization of farnesyl diphosphate (2, FPP) to the tricyclic sesquiter

26 Incubation of (1R)-[1-(2)H]farnesyl diphosphate (2b) with recombinant presilphiperf

27 Cyclization of [13,13,13-(2)H(3)] farnesyl diphosphate (2d) gave [14,14,14-(2)H(3)]-3d, th

28 alogues of geranyl diphosphate (3-ClGPP) and farnesyl diphosphate (3-ClFPP), respectively.

29 Recombinant Mg25 converted farnesyl diphosphate (C(15)) predominantly to beta-cubeb

30 gh either geranyl diphosphate (C10) or trans-farnesyl diphosphate (C15), to yield monoterpenes and se

31 enzyme GGDP synthase (GGDPS) that condenses farnesyl diphosphate (FDP) and isopentenyl pyrophosphate

32 10-geranyl diphosphate (GDP) and only 4% C15-farnesyl diphosphate (FDP) in the presence of Co(2+) or

33 in order of increasing potency at inhibiting farnesyl diphosphate (FDP) synthase (their intracellular

34 zes the metal-dependent cyclization of (E,E)-farnesyl diphosphate (FDP) to the cadinane sesquiterpene

35 idago canadensis catalyzes the conversion of farnesyl diphosphate (FDP) to the plant sesquiterpene (+

36 products from its natural substrate (2E,6E)-farnesyl diphosphate (FDP).

37 Farnesyl diphosphate (FPP) analogues have proven to be b

38 trates for modification with the isoprenoids farnesyl diphosphate (FPP) and anilinogeranyl diphosphat

39 The polyisoprenoid diphosphates farnesyl diphosphate (FPP) and geranylgeranyl diphosphat

40 Farnesyl diphosphate (FPP) and geranylgeranyl diphosphat

41 ly synthesizes the "regular" sesquiterpenoid farnesyl diphosphate (FPP) by coupling isopentenyl dipho

42 ous or monitor pyrophosphate release and not farnesyl diphosphate (FPP) creation.

43 tep in its biosynthesis, condensation of two farnesyl diphosphate (FPP) molecules to dehydrosqualene,

44 transfer of a 15-carbon farnesyl group from farnesyl diphosphate (FPP) to a conserved cysteine in th

45 an initial condensation of two molecules of farnesyl diphosphate (FPP) to form presqualene diphospha

46 yzes the ionization-dependent cyclization of farnesyl diphosphate (FPP) to form the bicyclic eremophi

47 talyzes the condensation of two molecules of farnesyl diphosphate (FPP) to give presqualene diphospha

48 Transfer of the farnesyl group from farnesyl diphosphate (FPP) to proteins is catalyzed by p

49 The universal sesquiterpene precursor, farnesyl diphosphate (FPP), is cyclized in an Mg(2+)-dep

50 -carbon geranyl diphosphate (GPP), 15-carbon farnesyl diphosphate (FPP), or 20-carbon geranylgeranyl

51 atom from the alpha- and beta-phosphates of farnesyl diphosphate (FPP).

52 and a sesquiterpene, nerolidol, derived from farnesyl diphosphate (FPP).

53 sphates were good alternative substrates for farnesyl diphosphate (FPP).

54 sphate (GPP) and between IPP and GPP to give farnesyl diphosphate (FPP).

55 Toxoplasma gondii possesses a bifunctional farnesyl diphosphate (FPP)/geranylgeranyl diphosphate (G

56 substrates neryl diphosphate (NPP) and 2Z,6Z-farnesyl diphosphate (Z,Z-FPP).

57 beetle protein extracts, but only when (Z,E)-farnesyl diphosphate [(Z,E)-FPP] was offered as a substr

58 yme active site, we conclude that folding of farnesyl diphosphate alone does not always dictate the s

59 Farnesyl diphosphate analogues with fluorine at C2 and C

60 The assays use [(3)H]farnesyl diphosphate and [(3)H]geranylgeranyl diphosphat

61 isoprenoid mevalonate pathway-intermediates, farnesyl diphosphate and geranylgeranyl diphosphate, als

62 anisms, is subject to feedback regulation by farnesyl diphosphate and related compounds.

63 The use of (2Z,6E)-farnesyl diphosphate as an alternate substrate for recom

64 e-catalyzed synthesis of sesquiterpenes from farnesyl diphosphate as high-value natural products with

65 picture of the conformation of enzyme-bound farnesyl diphosphate at the active site of presilphiperf

66 o be involved in isopentenyl diphosphate and farnesyl diphosphate biosynthesis leading to AN were not

67 essarily reflect the original orientation of farnesyl diphosphate bound in the corresponding enzyme a

68 osphate bound and with the product mimic E,E-farnesyl diphosphate bound.

69 ation of isopentenyl diphosphate (IPP), with farnesyl diphosphate catalysed by a cis-isoprenyltransfe

70 ogenes lacking conserved motifs required for farnesyl diphosphate cyclase activity.

71 ed with the SNP rs2645424 on chromosome 8 in farnesyl diphosphate farnesyl transferase 1 (FDFT1) (P =

72 emethylase (CYP51A1), and squalene synthase (farnesyl diphosphate farnesyl transferase 1)) via novel

73 te synthase (FPS) catalyzes the synthesis of farnesyl diphosphate from isopentenyl diphosphate and di

74 n adds a further seven isoprene units to E,Z-farnesyl diphosphate in a processive manner to generate

75 ne cyclase that catalyzes the cyclization of farnesyl diphosphate in the first committed step of the

76 ta-caryophyllene and alpha-humulene from E,E-farnesyl diphosphate in trichomes of leaf but not of ste

77 f the tomato sesquiterpene synthases use z,z-farnesyl diphosphate in vitro as well, or more efficient

78 TCs from Dictyostelium discoideum converted farnesyl diphosphate into (2S,3R,6S,9S)-(-)-protoillud-7

79 hese results established that cyclization of farnesyl diphosphate involves displacement of the diphos

80 may be significantly more selective for the farnesyl diphosphate substrate than the active site bind

81 o as well, or more efficiently than, the e,e-farnesyl diphosphate substrate.

82 eactions, chimeric proteins constructed from farnesyl diphosphate synthase (chain elongation) and chr

83 Farnesyl diphosphate synthase (FDPS) catalyzes the conve

84 stimulate Vgamma2Vdelta2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate p

85 Farnesyl diphosphate synthase (FDPS), a mevalonate pathw

86 y unrecognized beta2AR regulators, including farnesyl diphosphate synthase (FDPS).

87 nts of the first two enzymes in the pathway, farnesyl diphosphate synthase (FDS) and carotenoid synth

88 The amino acid sequences of farnesyl diphosphate synthase (FPPase) and chrysanthemyl

89 esized and evaluated as substrates for avian farnesyl diphosphate synthase (FPPase).

90 r therapeutic agents involving inhibition of farnesyl diphosphate synthase (FPPS) and geranylgeranyl

91 s modulated by the lipid biosynthesis enzyme farnesyl diphosphate synthase (FPPS).

92 r possible binding to the allosteric site in farnesyl diphosphate synthase (FPPS).

93 Farnesyl diphosphate synthase (FPS) catalyzes the synthe

94 ylgeranyl diphosphate synthase (LiGGPPS) and farnesyl diphosphate synthase (LiFPPS).

95 related Z-prenyl diphosphate synthases, E,Z-farnesyl diphosphate synthase (Rv1086) and decaprenyl di

96 n at the low nanomolar level of the T. cruzi farnesyl diphosphate synthase (TcFPPS).

97 neryl diphosphate synthase1 (NDPS1) and Z,Z-farnesyl diphosphate synthase (zFPS), which are encoded

98 y by the targeted overexpression of an avian farnesyl diphosphate synthase along with two versions of

99 Farnesyl diphosphate synthase catalyzes the sequential c

100 We screened 26 bisphosphonates against a farnesyl diphosphate synthase from Plasmodium vivax, fin

101 ncer cells to pitavastatin is potentiated by farnesyl diphosphate synthase inhibitors or geranylgeran

102 re excellent competitive inhibitors of avian farnesyl diphosphate synthase with KI = 1.0 +/- 0.12 muM

103 3-hydroxy-3-methylglutaryl-CoA reductase or farnesyl diphosphate synthase, reduced endometrial organ

104 ar to the isoprenoid chain elongation enzyme farnesyl diphosphate synthase, which also contains two a

105 similar in some respects to that of dimeric farnesyl diphosphate synthase, which is not a cyclase.

106 (nBPs) are bone-specific agents that inhibit farnesyl diphosphate synthase.

107 IP and DMAP can also competitively inhibit farnesyl diphosphate synthase.

108 synthesize long-chain trans-polyisoprene via farnesyl diphosphate synthases (FPSs).

109 zes the conversion of two molecules of (E,E)-farnesyl diphosphate to squalene via the cyclopropylcarb

110 e synthase that catalyzes the cyclization of farnesyl diphosphate to the novel tricyclic hydrocarbon,

111 step in HA biosynthesis is the conversion of farnesyl diphosphate to trichodiene (TD), a volatile org

112 , whereas VoTPS1 catalyzes the conversion of farnesyl diphosphate to valerena-1,10-diene.

113 ations of isotopically pure [2-(2)H(1)](E,E)-farnesyl diphosphate with recombinant patchoulol synthas

114 Incubation of farnesyl diphosphate with recombinant yeast squalene syn

115 phate, generating the 15-carbon product (E,Z-farnesyl diphosphate).

116 diphosphate and dimethylallyl diphosphate to farnesyl diphosphate, a crucial metabolic intermediate i

117 e synthase (FPPS) catalyzes the synthesis of farnesyl diphosphate, an important precursor of sterols,

118 was inactive, whereas the LSU produced GPP, farnesyl diphosphate, and geranylgeranyl diphosphate (GG

119 l cation, the product of 11,1-cyclization of farnesyl diphosphate, is the product of the first commit

120 ion that following the initial ionization of farnesyl diphosphate, minimal enzymatic intervention may

121 noterpene synthases and three that preferred farnesyl diphosphate, the substrate for sesquiterpene sy

122 on of the universal sesquiterpene precursor, farnesyl diphosphate, to form the bicyclic hydrocarbon a

123 scherichia coli, and demonstrated to cyclize farnesyl diphosphate, yielding beta-selinene as the domi

124 fuels and the rapid engineering of microbial farnesyl diphosphate-overproducing platforms for the pro

125 phate substrates neryl diphosphate and 2z,6z-farnesyl diphosphate.

126 ion mixtures of L-tryptophan with geranyl or farnesyl diphosphate.

127 lly phosphorylated to farnesyl phosphate and farnesyl diphosphate.

128 tosolic and reported to act on the 15-carbon farnesyl diphosphate.

129 as altered templates for the cyclization of farnesyl diphosphate.

130 he total hydrocarbons obtained using (2E,6E)-farnesyl diphosphate.

131 g to the synthesis of farnesene isomers from farnesyl diphosphate.

132 out a gene for biosynthesis of the precursor farnesyl diphosphate.

133 squiterpene synthases, exclusively using Z-Z-farnesyl-diphosphate (zFPP) in plastids, probably arisen

134 ll interfering RNA showed that inhibition of farnesyl-diphosphate farnesyl transferase (squalene synt

135 Farnesyl-diphosphate synthase (FPPS) catalyzes the synth

136 nd characterization of two Toxoplasma gondii farnesyl-diphosphate synthase (TgFPPS) homologs.

137 Through the addition of prenyl transferases, farnesyl diphosphates, (2E,6E)-FDP and (2Z,6Z)-FDP, were

138 We characterized a farnesyl-electrostatic switch whereby protein kinase C p

139 the opposite preference of tH palmitoyls and farnesyl for ordered and disordered membrane domains, cl

140 reaction requires farnesyldiphosphate as the farnesyl group donor and is catalyzed by the farnesyltra

141 se (FTase) catalyzes transfer of a 15-carbon farnesyl group from farnesyl diphosphate (FPP) to a cons

142 Transfer of the farnesyl group from farnesyl diphosphate (FPP) to protei

143 on of geranyl diphosphate (GPP) with the cis-farnesyl group in phosphoglycolipid 5 to form the (C25)

144 cs simulations collectively suggest that the farnesyl group is sequestered within a hydrophobic regio

145 Farnesylation, the attachment of a 15-carbon farnesyl group near the C-terminus of protein substrates

146 s achieved by enzymatically transferring the farnesyl group of the farnesyl-CoA micelle onto a peptid

147 whereas the rigid microdomains restrict the farnesyl group penetration.

148 The farnesyl group spontaneously inserts into the disordered

149 peptide pheromone conjugated to a C-terminal farnesyl group that makes it very hydrophobic.

150 FTase catalyzes the transfer of a farnesyl group to a conserved cysteine residue (Cys1p) o

151 The docking of the farnesyl group to the hydrophobic pockets located at bot

152 In some cases the farnesyl group was apparently split off from the peptide

153 s protein is permanently modified by a lipid farnesyl group, and acts as a dominant negative, disrupt

154 normal cleavage site to remove a C-terminal farnesyl group.

155 hich Gt can anchor through its myristoyl and farnesyl groups.

156 hat the GDP/GTP exchange, HVR sequestration, farnesyl insertion, and orientation/localization of the

157 AIPL1, deletion of which also abolished the farnesyl interaction.

158 y contribution of the two palmitates and the farnesyl is additive, was not known.

159 ur results suggest that the binding of PDE6A farnesyl is essential to normal function of AIPL1 and it

160 d their prenylation with a geranylgeranyl or farnesyl isoprenoid moiety and subsequent trafficking to

161 rate for posttranslational modification by a farnesyl isoprenoid.

162 Progerin retains a farnesyl lipid anchor at its carboxyl terminus, a modifi

163 We propose that the farnesyl lipid binds to a site at the opening of two tra

164 inhibitor (FTI), suggesting that progerin's farnesyl lipid is important for disease pathogenesis and

165 Whether RD is caused by the retention of farnesyl lipid on prelamin A, or by the retention of the

166 se (FTase) catalyzes transfer of a 15 carbon farnesyl lipid to cysteine in the C-terminal Ca1a2X sequ

167 c ykt6 is normally autoinhibited by a unique farnesyl-mediated regulatory mechanism; however, during

168 phorylation of Ser-181 prohibits spontaneous farnesyl membrane insertion.

169 fic HVR binding to anionic phospholipids but farnesyl membrane orientation.

170 Ras isoforms, K-Ras4B HVR contains a single farnesyl modification and positively charged polylysine

171 as4B is targeted to the plasma membrane by a farnesyl modification that operates in conjunction with

172 trifluoromethoxy-AGPP gave both analogue and farnesyl modified dansyl-GCVIM but only farnesylated dan

173 Lipid anchors composed of palmitoyl and farnesyl moieties in H-, N-, and K-Ras are widely suspec

174 rfactant molecule in a micelle, pointing the farnesyl moieties into the hydrophobic center and positi

175 rminus of Rnd3 consisting of both the Cys241-farnesyl moiety and a Rho-associated coiled coil contain

176 The combined action of a farnesyl moiety and zinc finger-like region enable Type

177 farnesyl moiety hidden state and an opened, farnesyl moiety exposed state represents the first phase

178 hydrolysis driven cycling between a closed, farnesyl moiety hidden state and an opened, farnesyl moi

179 l hypervariable region and carboxymethylated farnesyl moiety, as shown by FPOP.

180 subunit through direct interaction with the farnesyl moiety, mutations compromising the integrity of

181 witch by modulating the accessibility of its farnesyl moiety, which does not require any supportive p

182 the hypothesis that AIPL1 directly binds the farnesyl moiety.

183 groove in 14-3-3 proteins accommodating the farnesyl moiety.

184 spectra often revealed a neutral loss of the farnesyl moiety.

185 rimarily prenylated, either with a 15-carbon farnesyl or a 20-carbon geranylgeranyl polyunsaturated l

186 Isoprenoids (i.e., farnesyl or geranylgeranyl groups) are attached to cyste

187 enyltransferase-catalyzed addition of either farnesyl or geranylgeranyl isoprenoid lipids, Rce1-catal

188 oteins resulting in the addition of either a farnesyl or geranylgeranyl isoprenyl lipid moiety to the

189 The modification of proteins with farnesyl or geranylgeranyl lipids, a process called prot

190 enylation, the specific prenyl modification (farnesyl or geranylgeranyl), as well as the prenyl-trans

191 enerated in a three-step sequence in which a farnesyl-pantetheine conjugate is phosphorylated, adenyl

192 ntrations, is sequentially phosphorylated to farnesyl phosphate and farnesyl diphosphate.

193 Farnesol and farnesyl phosphate kinases have also been reported in pl

194 agonists is alkyl glycerol phosphate > LPA > farnesyl phosphates >> N-arachidonoylglycine.

195 lysine-POPG salt bridges and by nonspecific farnesyl-phospholipid van der Waals interactions.

196 synthesis of an internally truncated form of farnesyl-prelamin A (progerin).

197 dings indicate that progerin and full-length farnesyl-prelamin A are toxic to neurons of the enteric

198 TE24, nor does it lead to an accumulation of farnesyl-prelamin A in cells.

199 cally modified mice that express full-length farnesyl-prelamin A in neurons (Zmpste24-deficient mice

200 ibit ZMPSTE24, leading to an accumulation of farnesyl-prelamin A.

201 Farnesyl protein transferase (FTase) or geranylgeranyl p

202 S, to date, successes of therapies targeting farnesyl protein transferase are modest.

203 vitro screen for resistance to lonafarnib, a farnesyl protein transferase inhibitor that blocks preny

204 on of imatinib and lonafarnib, we identified farnesyl protein transferase mutations in residues ident

205 we demonstrate that an inhibitor of p21(ras) farnesyl protein transferase suppressed the expression o

206 almitoyl), RhoA (geranylgeranyl), and K-Ras (farnesyl) proteins in different cell types.

207 We speculate that the resulting farnesyl protrusion toward the cell interior allows olig

208 urs) in the absence (control) or presence of farnesyl pyrophosphate (10 muM) or geranylgeranyl pyroph

209 he synthesis of the wound-healing inhibitors farnesyl pyrophosphate (FPP) and cortisol, ligands for t

210 by depleting mevalonate pathway metabolites farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos

211 hese events were significantly attenuated by farnesyl pyrophosphate (FPP) but not by geranylgeranyl p

212 Augmentation of the metabolic flux to farnesyl pyrophosphate (FPP) by different FPP synthases

213 of the 15-carbon sterol pathway intermediate farnesyl pyrophosphate (FPP) cause increased Hmg2p ubiqu

214 ructure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat F

215 We apply this approach to regulate farnesyl pyrophosphate (FPP) production in the isoprenoi

216 roposed for the carbocationic cyclization of farnesyl pyrophosphate (FPP) to (+)-aristolochene cataly

217 ules of isopentenyl pyrophosphate (IPP) with farnesyl pyrophosphate (FPP) to generate the C(55) undec

218 Farnesyl pyrophosphate (FPP), a key intermediate in the

219 MEV, squalene and ergosterol, as well as the farnesyl pyrophosphate (FPP)-derived side products farne

220 yzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).

221 e inhibitor GGTI-298, and prenyl substrates (farnesyl pyrophosphate [FPP] and geranylgeranyl pyrophos

222 A biomimetic route to farnesyl pyrophosphate and dimethyl orsellinic acid (DMO

223 tidic acid receptor with weaker responses to farnesyl pyrophosphate and geranylgeranyl diphosphate.

224 gly, the levels of the cholesterol precursor farnesyl pyrophosphate and its derivative geranylgeranyl

225 ived from dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have attracted much biosynthetic

226 from 3,5-dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have not been reported despite he

227 umoral effects through the modulation of the farnesyl pyrophosphate synthase (FPPS) activity.

228 that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, p

229 he 5 alpha-halo-analogues potently inhibited farnesyl pyrophosphate synthase (FPPS) with IC50 values

230 its most firmly established cellular target, farnesyl pyrophosphate synthase (FPPS).

231 Human farnesyl pyrophosphate synthase (hFPPS) controls intrace

232 Human farnesyl pyrophosphate synthase (hFPPS) controls the pos

233 Human farnesyl pyrophosphate synthase (hFPPS) is the gate-keep

234 The human farnesyl pyrophosphate synthase (hFPPS), a key regulator

235 ine-based allosteric inhibitors of the human farnesyl pyrophosphate synthase (hFPPS), characterized b

236 nomenon strongly augmented by zoledronate, a farnesyl pyrophosphate synthase inhibitor that increases

237 ntaining bisphosphonate zoledronate inhibits farnesyl pyrophosphate synthase, a key enzyme of the mev

238 any, IPP and expressed much lower levels of farnesyl pyrophosphate synthase.

239 e gene encoding a phosphatase which converts farnesyl pyrophosphate to farnesol.

240 carboxamide ribotide (ZMP), GDP-mannose, and farnesyl pyrophosphate were found to be rapidly altered

241 we designed protein sensors that respond to farnesyl pyrophosphate, a metabolic intermediate in the

242 te and geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, abolished these anticontractile

243 Statins block production of farnesyl pyrophosphate, an intermediate in the synthesis

244 y hydroxymethylglutaryl-CoA, mevalonate, and farnesyl pyrophosphate, but not cholesterol and ubiquino

245 e isoprenoid biosynthetic pathway leading to farnesyl pyrophosphate, the immediate molecular precurso

246 e or geranylgeranyl pyrophosphate but not by farnesyl pyrophosphate.

247 formed both caryophyllene and humulene from farnesyl pyrophosphate.

248 es, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate.

249 odel of MS are via depletion of isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate)

250 ygeranyl-pyrophosphate is more critical than farnesyl-pyrophosphate in glial cells.

251 or geranylgeranyl-pyrophosphate, but not by farnesyl-pyrophosphate or cholesterol, suggesting that d

252 e to HMG-CoA reductase (upstream enzyme) and farnesyl-pyrophosphate synthase, respectively.

253 ing a palladium catalyzed decarboxylative pi-farnesyl rearrangement of a diketo-dioxinone ester, arom

254 ogy approach, we identify ROD as the Spindly farnesyl receptor.

255 ) ions and the unreactive substrate analogue farnesyl-S-thiolodiphosphate (FSPP), showing that the su

256 in an open conformational state; the heme a farnesyl sidechain is H-bonded to S382, and loop-I-II ad

257 Among numerous approaches, nitration of a 3-farnesyl-substituted unprotected pyrrole using AcONO2 ga

258 ing both the porphyrin ring and the hydroxyl farnesyl tail, accompanied by protein movements in nearb

259 lta exhibit a hydrophobic binding pocket for farnesyl, they have different effects on membrane bindin

260 ipid compounds (farnesyl thiosalicylic acid, farnesyl thioacetic acid, 15-deoxy-Delta(12,14)-prostagl

261 ary complex of the rat enzyme incubated with farnesyl thiodiphosphate (FSPP) are reported.

262 drophobic pocket previously reported to bind farnesyl thiodiphosphate (FsPP), as well as biphenyl pho

263 Farnesyl thiodiphosphate competes with substrate ATP to

264 ion conditions; this results in detection of farnesyl thiophosphate (FSP) in the structure of the bin

265 Farnesyl thiosalicylic acid activates the channel in exc

266 ant, we show that the mechanism of action of farnesyl thiosalicylic acid differs from that of the rea

267 ith a potentially novel mechanism of action, farnesyl thiosalicylic acid may be useful in the study o

268 activity, including several lipid compounds (farnesyl thiosalicylic acid, farnesyl thioacetic acid, 1

269 ggest that while Cys181-palmitate and Cys186-farnesyl together provide sufficient hydrophobic force f

270 , interleukin-1beta (IL-1beta), statins, the farnesyl transferase (FT) inhibitor FTI-276 and geranylg

271 used on the development of selective protein farnesyl transferase (FTase) and protein geranylgeranyl

272 Protein farnesyl transferase (FTase) catalyzes transfer of a 15

273 Protein farnesyl transferase (FTase) catalyzes transfer of a 15-

274 rovision of structure-specific inhibitors of farnesyl transferase (FTase; e.g., FTI-277 or FTI-2628)

275 f both geranylgeranyl transferase (GGTI) and farnesyl transferase (FTI) inhibited the activation of N

276 Protein farnesyl transferase (PFTase) is able to site-specifical

277 owed that inhibition of farnesyl-diphosphate farnesyl transferase (squalene synthase), but not 3-hydr

278 5424 on chromosome 8 in farnesyl diphosphate farnesyl transferase 1 (FDFT1) (P = 6.8 x 10(-7)).

279 and squalene synthase (farnesyl diphosphate farnesyl transferase 1)) via novel negative LXR DNA resp

280 In cells with chronically inhibited farnesyl transferase activity, in vitro farnesylation an

281 of Smad3 results in increased inhibition of farnesyl transferase activity.

282 ploying cell-permeable inhibitors of protein farnesyl transferase and geranylgeranyl transferase enzy

283 rest in their biology and the development of farnesyl transferase and geranylgeranyl transferase inhi

284 ED RESPONSE TO ABA1 (ERA1), that encodes the farnesyl transferase beta-subunit.

285 Inhibition of farnesylation using a farnesyl transferase inhibitor (FTI) abrogated hSpindly

286 le the ortho-substituted isomer was a potent farnesyl transferase inhibitor (FTI) with an inhibition

287 oll onto a single-arm, open-label trial of a farnesyl transferase inhibitor for patients with HRAS mu

288 he mechanism of mTOR activation, we used the farnesyl transferase inhibitor FTI-277, which partially

289 Furthermore, inactivation of Ras by farnesyl transferase inhibitor or K-Ras small interferin

290 not by an inhibitor of farnesyl-transferase (farnesyl transferase inhibitor-277).

291 This effect was reversed by farnesyl transferase inhibitors and by the addition of g

292 These data suggest that farnesyl transferase inhibitors should be reevaluated as

293 the presence of a mutant allele of the Cox10 farnesyl transferase involved in heme a biosynthesis or

294 measure the degree of protein prenylation by farnesyl transferase or geranylgeranyl transferase in vi

295 inose synthase, trehalose synthase, amylase, farnesyl transferase, catalase, methyl transferase, lina

296 ihydrochloride)]} but not by an inhibitor of farnesyl-transferase (farnesyl transferase inhibitor-277

297 naling by small interfering RNA (siRNA) or a farnesyl-transferase inhibitor decreases KLF6 SV1 and su

298 Growth inhibition by farnesyl-transferase inhibitor in transformed cell lines

299 ike compounds with 1'-3 linkages between the farnesyl units.

300 le in regulation of nuclear receptors [e.g., farnesyl X receptor (FXR)], leading to enhanced or suppr